8 Results for "

worm burdens

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "worm burdens" in MCE Product Catalog:

45
45 Cited Publications
Cat. No.: HY-N0176
CAS No.: 71939-50-9
Synonyms: Dihydroqinghaosu; β-Dihydroartemisinin; Artenimol
Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection .
loading...
    loading...
Cat. No.: HY-B1073
CAS No.: 26155-31-7
Target:  

Parasite

Research Areas:  

Infection

Morantel tartrate is an anthelmintic agent. Sustained-release three-layer composite tablets of Morantel tartrate are administered orally and release after exposure to rumen fluid. Morantel tartrate reduces the fecal egg output and worm burden of gastrointestinal nematodes in Hereford calves. Morantel tartrate is used in research related to gastrointestinal nematode infections .
loading...
    loading...
Cat. No.: HY-N0176R
CAS No.: 71939-50-9
Synonyms: Dihydroqinghaosu (Standard); β-Dihydroartemisinin (Standard); Artenimol (Standard)
Dihydroartemisinin (Standard) (Dihydroqinghaosu (Standard)) is the analytical standard of Dihydroartemisinin (HY-N0176). This product is intended for research and analytical applications. Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection .
loading...
    loading...
Cat. No.: HY-N0176S
CAS No.: 176774-98-4
Synonyms: Dihydroqinghaosu-d3; β-Dihydroartemisinin-d3; Artenimol-d3
Dihydroartemisinin-d3 (Dihydroqinghaosu-d3) is the d3-labeled Dihydroartemisinin (HY-N0176). Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection .
loading...
    loading...
Cat. No.: HY-124018
CAS No.: 4300-43-0
Target:  

Parasite

Research Areas:  

Infection

MMV665852 is an antischistosomal agent that inhibits worm viability in vitro. MMV665852 reduces worm burden in mice infected with Schistosoma mansoni.
loading...
    loading...
Cat. No.: HY-N0176S3
Synonyms: Dihydroqinghaosu-d5; β-Dihydroartemisinin-d5; Artenimol-d5
Dihydroartemisinin-d5 (Dihydroqinghaosu-d5) is the d5-labeled Dihydroartemisinin (HY-N0176). Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection .
loading...
    loading...
Cat. No.: HY-187528
Target:  

Parasite

Research Areas:  

Infection

GPCR antagonist-2 is a GPCR antagonist with macrofilaricidal activity. GPCR antagonist-2 shows inhibitory effects on Brugia pahangi adult females and males (IC50 = 3.9 μM and 2.8 μM, respectively) and Onchocerca ochengi adult females and males (IC50 = 0.35 μM and 1.7 μM, respectively). GPCR antagonist-2 reduces B. pahangi worm burden and affects female fecundity and embryogenesis, downregulates GPCR expression in surviving adult female worms and can be used for the study of filarial infections, including onchocerciasis (river blindness) .
loading...
    loading...
Cat. No.: HY-N0176S6
CAS No.: 252043-36-0
Synonyms: Dihydroqinghaosu-d; β-Dihydroartemisinin-d; Artenimol-d
Dihydroartemisinin-d (Dihydroqinghaosu-d) is the d-labeled Dihydroartemisinin (HY-N0176). Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection .
loading...
    loading...